Novartis Drops Up to $745M to Move Deeper Into Competitive …

4 days ago · Novartis has struck a deal worth up to $745 million with Ratio Therapeutics for a radiopharmaceutical that could help defend its franchise from would-be challengers including …

CouponFollow Extension

$745
OFF

Novartis Drops Up To $745M To Move Deeper Into Competitive …

6 days from now

4 days ago · Novartis has struck a deal worth up to $745 million with Ratio Therapeutics for a radiopharmaceutical that could help defend its franchise from would-be challengers including …

biospace.com

$745
OFF

Novartis Taps Ratio For $745M Radiopharmaceutical Pact

6 days from now

Nov 15, 2024 · Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth $745 million in biobucks for rights to a cancer candidate from Ratio Therapeutics. …

fiercebiotech.com

$745
OFF

Novartis Inks $745M Radiopharma Partnership With Ratio …

6 days from now

4 days ago · Novartis has also been examining Lutathera for other indications. In September, it released Phase 2 data on Lutathera improving progression-free survival in patients with …

mmm-online.com

$745
OFF

Novartis Expands Radiopharmaceutical Portfolio With $745M Deal …

6 days from now

5 days ago · Novartis has struck a licensing agreement with Boston-based biotech Ratio Therapeutics, securing global rights to a promising cancer candidate targeting somatostatin …

biopharmatrend.com

$745
OFF

Novartis Signs Deal With Mass. Company Worth Up To $745M

6 days from now

4 days ago · The deal with Novartis will use Ratio’s expertise and technology to develop a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer. ...

bizjournals.com

$745
OFF

Ratio Therapeutics Lands $745M Cancer Drug Development Deal …

6 days from now

5 days ago · Ratio Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG to develop a Somatostatin Receptor 2 (SSTR2) …

stocktitan.net

$745
OFF

Novartis Invests $745M To Compete With BMS And Lilly In The …

6 days from now

4 days ago · N ovartis has partnered with Ratio Therapeutics in a deal potentially worth up to $745 million to develop a radiopharmaceutical targeting somatostatin receptor 2 (SSTR2) for …

geneonline.com

$750
OFF

Ratio Nets Potential $750M Radioligand Cancer Deal With Novartis

6 days from now

4 days ago · Ratio Therapeutics has inked an exclusive worldwide agreement potentially worth $745M with Novartis Pharma AG. The collaboration leverages Ratio’s radioligand therapy …

insideprecisionmedicine.com

$63
OFF

Novartis Strengthens Radiopharma Leadership With Ratio …

6 days from now

Venture financing for innovative radiopharmaceutical drugs witnessed an increase from $63m in 2017 to over $400m in 2023 total deal value in the US, according to GlobalData’s Pharma …

msn.com

$745
OFF

Novartis Continues Push Into Radiopharma With $745M Ratio Deal

6 days from now

5 days ago · With two approved radioligand therapies on its commercial roster and a recent plan to boost its manufacturing for radiotherapeutics, Novartis AG tapped Ratio Therapeutics Inc. in …

bioworld.com

$745
OFF

Novartis Strikes Radiopharma Deal With Ratio Worth Up To $745M

6 days from now

5 days ago · Novartis and Ratio Therapeutics announced a collaboration deal worth up to $745 million, focusing on SSTR2 radiotherapeutic cancer treatment. Ratio will receive an …

endpts.com

$1
OFF

Novartis Entrenches Into Radiopharma With $1B Mariana Buy

6 days from now

May 2, 2024 · This is the second deal Novartis has signed with a radioligand-focused company this week, behind a $180 million licensing agreement with PeptiDream. Malek said both these …

fiercebiotech.com

$425
OFF

Novartis Knows What's Ahead As Peers Enter Radiopharmaceuticals

6 days from now

Oct 24, 2023 · Novartis pens $425M biobucks deal with German biotech, scooping up more radiopharmaceutical tech Not just anyone can walk in and start working with a …

fiercebiotech.com

$745
OFF

Novartis News | Latest News - NewsNow

6 days from now

Novartis, Ratio sign radiopharmaceutical pact to the tune of $745M biobucks FierceBiotech 3d FierceBiotech 3d Novartis and Schrödinger to advance drug candidates in deal worth over …

newsnow.com

FAQs about Novartis Drops Up to $745M to Move Deeper Into Competitive … Coupon?

How much money will ratio receive from Novartis?

Under the terms of the agreement, Ratio will receive combined upfront and potential milestone payments up to $745m, and is eligible to receive tiered royalty payments. Ratio will collaborate with Novartis to drive preclinical activities to research and select an SSTR2-targeting development candidate. ...

Does Novartis need a big move?

The CEO said the biotech didn’t need to make a big move like this after raising $175 million late last year in a series B, but Mariana had caught the attention of potential buyers. Novartis had recently been joined by peers Lilly and Bristol Myers Squibb in the radiopharmaceuticals space with plenty of deal action. ...

What is Novartis doing with radioligand therapy?

In the announcement accompanying the deal, Novartis’ president of biomedical research Fiona Marshall said: “Radioligand therapies hold transformative potential for certain forms of cancer, and Novartis is committed to maximising their impact by continually improving the benefit for patients.” ...

Is ratio partnering with Novartis to develop a new sstr2-targeting therapy?

"The team at Ratio is honored and excited to partner with Novartis on the development of a next-generation SSTR2-targeting therapeutic," said Jack Hoppin, Ph.D., Chief Executive Officer of Ratio. "Together, we aim to develop a best-in-class therapy in the fight against SSTR2-expressing tumors." ...

What will Novartis do with SSTR2?

The collaboration focuses on preclinical research to identify an SSTR2-targeting development candidate, after which Novartis will take the lead on development, manufacturing, and commercialisation. A protein overexpressed in various cancers, SSTR2 is a key target for therapies due to its role in enabling precise and targeted treatment. ...

What is Novartis NewsNow?

GlobeNewswire (Press Release) 08:13 23-Nov-22 NewsNow aims to be the world's most accurate and comprehensive aggregator of Novartis news, covering the latest share price, company announcements, product trials, pharmaceutical news and more from the best online publications. ...